<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-4598-2-22</article-id><article-id pub-id-type="pmid">12740040</article-id><article-id pub-id-type="doi">10.1186/1476-4598-2-22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>SLC/CCL21-mediated anti-tumor responses require IFN&#x003b3;, MIG/CXCL9 and IP-10/CXCL10</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Sharma</surname><given-names>Sherven</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>sharmasp@ucla.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Yang</surname><given-names>Seok-Chul</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yangsc@ucla.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hillinger</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hillings@ucla.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Zhu</surname><given-names>Li X</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>LZhu@mednet.ucla.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Huang</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>minhuang@ucla.edu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Batra</surname><given-names>Raj K</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>rbatra@ucla.edu</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Lin</surname><given-names>Jeff F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>j-lin5@northwestern.edu</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Burdick</surname><given-names>Marie D</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>MBurdick@mednet.ucla.edu</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Strieter</surname><given-names>Robert M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>RStrieter@mednet.ucla.edu</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Dubinett</surname><given-names>Steven M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>SDubinett@mednet.ucla.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medicine, UCLA Lung Cancer Research Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA</aff><aff id="I2"><label>2</label>Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA</aff><aff id="I3"><label>3</label>Molecular Gene Medicine Laboratory, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA</aff><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2003</year></pub-date><volume>2</volume><fpage>22</fpage><lpage>22</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/2/1/22"/><history><date date-type="received"><day>28</day><month>3</month><year>2003</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2003</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2003 Sharma et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2003</copyright-year><copyright-holder>Sharma et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>SLC/CCL21, normally expressed in high endothelial venules and in T cell zones of spleen and lymph nodes, strongly attracts T cells and dendritic cells (DC). We have previously shown that SLC/CCL21-mediated anti-tumor responses are accompanied by significant induction of IFN&#x003b3; and the CXC chemokines, monokine induced by IFN&#x003b3; (MIG/CXCL9) and IFN&#x003b3;-inducible protein-10 (IP-10/CXCL10).</p></sec><sec><title>Results</title><p>We assessed the importance of IFN&#x003b3;, IP-10/CXCL10 and MIG/CXCL9 in SLC/CCL21 therapy. <italic>In vivo </italic>depletion of IP-10/CXCL10, MIG/CXCL9 or IFN&#x003b3; significantly reduced the anti-tumor efficacy of SLC/CCL21. Assessment of cytokine production at the tumor site showed an interdependence of IFN&#x003b3;, MIG/CXCL9 and IP-10/CXCL10; neutralization of any one of these cytokines caused a concomitant decrease in all three cytokines. Similarly, neutralization of any one of these cytokines led to a decrease in the frequency of CXCR3<sup>+ve </sup>T cells and CD11c<sup>+ve </sup>DC at the tumor site.</p></sec><sec><title>Conclusion</title><p>These findings indicate that the full potency of SLC/CCL21-mediated anti-tumor responses require in part the induction of IFN&#x003b3;, MIG/CXCL9 and IP-10/CXCL10.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>SLC/CCL21, normally expressed in high endothelial venules and in T cell zones of spleen and lymph nodes, strongly attracts T cells and dendritic cells (DC) [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. SLC/CCL21 recruits both na&#x000ef;ve lymphocytes and antigen stimulated DC into T cell zones of secondary lymphoid organs, co-localizing these early immune response constituents that culminate in cognate T cell activation [<xref ref-type="bibr" rid="B1">1</xref>]. The capacity to facilitate the co-localization of both DC and T cells forms a strong rationale for the use of SLC/CCL21 in cancer therapy. In previous studies we have shown that the SLC/CCL21-mediated anti-tumor responses are accompanied by the enhanced elaboration of IFN&#x003b3;, IP-10/CXCL10, MIG/CXCL9, GM-CSF and IL-12, but decreased PGE<sub>2</sub>, VEGF, IL-10, and TGF-&#x003b2; at the tumor site [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. In addition, there was a marked increase in CD4<sup>+ </sup>and CD8<sup>+ </sup>cells secreting IFN&#x003b3; and GM-CSF as well as DC expressing CD11c infiltrating the tumors. MIG/CXCL 9 and IP-10/CXCL10 are glutamine-leucine-arginine (ELR)-negative CXC chemokines that are potent chemoattractants for activated T cells [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. These chemokines also have in common the ability to signal through a G protein-coupled receptor, CXCR3, expressed on activated T lymphocytes. IP-10/CXCL10, MIG/CXCL9 and IFN&#x003b3; are known to have potent anti-tumor activities <italic>in vivo </italic>[<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Both MIG/CXCL9 and IP-10/CXCL10 are important for the anti-tumor activity mediated by IFN&#x003b3; inducing cytokines such as IL-12 [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Based on these findings we hypothesized that augmentation in IFN&#x003b3;, MIG/CXCL9, and IP-10/CXCL10 would play an important role in the SLC/CCL21-mediated anti-tumor response. Here we show that the cytokines IFN&#x003b3;, IP-10/CXCL10 and MIG/CXCL9 serve as effector molecules in SLC/CCL21-mediated anti-tumor responses.</p></sec><sec><title>Results and Discussion</title><p>Host antigen presenting cells (APC) are critical for the cross-presentation of tumor antigens [<xref ref-type="bibr" rid="B20">20</xref>]. However tumors have the capacity to limit APC maturation, function and infiltration of the tumor site [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. Thus molecules that attract host APC and T cells could serve as potent agents for cancer immunotherapy. A potentially effective pathway to restore Ag presentation is the establishment of a chemotactic gradient that favors localization of both activated DC and Type 1 cytokine producing lymphocytes at the tumor site. SLC/CCL21, a CC chemokine expressed in high endothelial venules and in T cell zones of spleen and lymph nodes, strongly attracts naive T cells and DCs [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. Because DCs are potent APCs that function as principal activators of T cells, the capacity to facilitate the co-localization of both DC and T cells may reverse tumor-mediated immune suppression and orchestrate effective cell-mediated immune responses [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. In addition to its immunotherapeutic potential, SLC/CCL21 has been found to have potent angiostatic effects [<xref ref-type="bibr" rid="B28">28</xref>], thus adding further support for its use in cancer therapy. Based on these dual capacities, we as well as others have begun pre-clinical evaluation of SLC/CCL21 in several tumor models [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>].</p><p>Utilizing two transplantable murine lung cancer models, we have previously shown that the anti-tumor efficacy of SLC/CCL21 is T cell-dependent [<xref ref-type="bibr" rid="B9">9</xref>]. In both models recombinant SLC/CCL21 administered intratumorally led to complete tumor eradication in 40 % of the treated mice. Studies performed in CD4 and CD8 knockout mice also revealed a requirement for both CD4 and CD8 lymphocytes subsets for SLC/CCL21 mediated tumor regression. Consistent with these findings we found that SLC therapy did not alter tumor growth in SCID mice. In immune competent mice, intratumoral injection of SLC/CCL21 led to a significant increase in CD4 and CD8 T lymphocytes as well as DC infiltrating the tumor and the draining lymph nodes. The cellular infiltrates were accompanied by an enhanced elaboration of IL-12, IFN&#x003b3;, IP-10/CXCL10 and MIG/CXCL9 at the tumor site [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>SLC/CCL21 is documented to have direct anti-angiogenic effects [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]; the tumor reductions observed in this model could have been due to participation by T cells secreting IFN&#x003b3; leading to inhibition of angiogenesis via MIG/CXCL9 and IP-10/CXCL10, as well as T cell-dependent immunity [<xref ref-type="bibr" rid="B16">16</xref>]. IFN&#x003b3; mediates a range of biological effects that facilitate anticancer immunity. MIG/CXCL9 and IP-10/CXCL10 are potent angiostatic factors that are induced by IFN&#x003b3; [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Both MIG/CXCL9 and IP-10/CXCL10 are chemotactic for stimulated CXCR3-expressing activated T lymphocytes that could further amplify IFN&#x003b3; at the tumor site [<xref ref-type="bibr" rid="B30">30</xref>]. Hence we postulated that in addition to IFN&#x003b3;, IP-10/CXCL10 and MIG/CXCL9 would also be important contributors to the tumor reduction in the context of SLC/CCL21 therapy.</p><p>To determine the importance of MIG/CXCL9, IP-10/CXCL10 and IFN&#x003b3; in the SLC/CCL21 mediated antitumor response, these cytokines were depleted in SLC/CCL21-treated mice. Anti-IP-10/CXCL10, MIG/CXCL9 and IFN&#x003b3; antibodies each partially but yet significantly inhibited the anti-tumor efficacy of SLC/CCL21 (Figure <xref ref-type="fig" rid="F1">1</xref> * p &#x0003c; 0.01 compared to the control antibody group). Neutralization of IFN&#x003b3; caused a significant decrease in both MIG/CXCL9 and IP-10/CXCL10 indicating that these chemokines are largely IFN&#x003b3; dependent. Thus, an increase in IFN&#x003b3; at the tumor site of SLC/CCL21-treated mice could explain the relative increases in IP-10/CXCL10 and MIG/CXCL9. The converse was also observed; IFN&#x003b3; production at the tumor site was found to be MIG/CXCL9- and IP-10/CXCL10-dependent as indicated by the fact that neutralization of these cytokines caused a significant decrease in IFN&#x003b3;(Figure <xref ref-type="fig" rid="F2">2</xref>). Neutralization of any one of these cytokines caused a concomitant decrease in all three cytokines, thus indicating that IFN&#x003b3;, MIG/CXCL9 and IP-10/CXCL10 are interdependent in the SLC/CCL21-mediated anti-tumor responses. Based on these findings, we speculated that the decrease of IP-10/CXCL10 and MIG/CXCL9 led to a decrease in IFN&#x003b3; by limiting the influx of T cells producing IFN&#x003b3; at the tumor site. Because MIG/CXCL9 and IP-10/CXCL10 are chemotactic for stimulated CXCR3 expressing activated T lymphocytes, we determined if neutralizing these chemokines <italic>in vivo </italic>in the SLC/CCL21-treated mice would decrease the frequency of CXCR3 expressing T cells at the tumor sites. Compared to SLC/CCL21-treated mice receiving control antibody, flow cytometric evaluation of single-cell suspensions of non-necrotic tumors from SLC/CCL21-treated mice receiving neutralizing antibodies to MIG/CXCL9, IP-10/CXCL10 and IFN&#x003b3; showed 10, 12 and 31 % decreases, respectively, in the gated CD3 CXCR3<sup>+ve </sup>T cell populations (Table <xref ref-type="table" rid="T1">1</xref>). The fact that neutralization of IFN&#x003b3; was the most efficient at decreasing the total number of CXCR3-activated T cells may be due to the decrease in the IFN&#x003b3;-dependent CXCR3 ligands MIG/CXCL9 and IP-10/CXCL10. Individually, neutralizing MIG/CXCL9 and/or IP-10/CXCL10 only led to a partial decrease in the total number of CXCR3-activated T cells. Because MIG/CXCL9 and IP-10/CXCL10 share the same receptor (CXCR3), one possible explanation of a partial decrease in CXCR3-activated T cells is that neutralization of one ligand may overexpose the receptor to the other ligand. Furthermore, because murine SLC/CCL21 binds CXCR3 receptor, SLC/CCL21 may be recruiting CXCR3<sup>+ve </sup>T cells directly. An alternative explanation is that residual cytokines such as IFN-inducible T cell &#x003b1; chemoattractant (ITAC/CXCL11) present after <italic>in vivo </italic>neutralization of IFN&#x003b3;, MIG, IP-10 may have remaining activity and attract CXCR3<sup>+ve </sup>T cells. Our results imply that all 3 cytokines, IFN&#x003b3;, MIG and IP-10 play interrelated roles in the recruitment of CXCR3-activated T cells in SLC/CCL21-mediated anti-tumor responses. While the number of CD4 and CD8 cells remained unaltered, compared to SLC/CCL21-treated mice receiving control antibody, mice administered neutralizing antibodies to MIG/CXCL9, IP-10/CXCL10 and IFN&#x003b3; showed respective decreases of 38, 28 and 16% in the number of CD11c<sup>+ </sup>DEC205<sup>+ </sup>DC infiltrating the tumor (Table <xref ref-type="table" rid="T1">1</xref>). At present it is not clear why there is a decrease in DC following neutralization of MIG/CXCL9, IP-10/CXCL10 and IFN&#x003b3;. A plausible explanation is that these cytokines may be involved in complex interactions with other molecules that are chemotactic for DC. Further studies are required to delineate the mechanisms responsible for MIG/CXCL9, IP-10/CXCL10 and IFN&#x003b3; mediated localization of DC at the tumor site.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>10 <sup>5 </sup>3 LL tumors were implanted in C57Bl/6 mice. 5 days following tumor implantation, mice were treated intratumorally with recombinant murine SLC/CCL21 (0.5 &#x003bc;g) 3X/week. One day before SLC/CCL21 administration, mice were given the respective cytokine antibody by i.p. injection. The antibodies were administered three times per week. Antibodies to: IP-10/CXCL10, MIG/CXCL9 and IFN&#x003b3; significantly inhibited the antitumor efficacy of SLC/CCL21 (*p &#x0003c; 0.01 compared to the control antibody treated group). n = 8 mice group</p></caption><graphic xlink:href="1476-4598-2-22-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>SLC/CCL21-treated mice had a significant induction in IFN&#x003b3;, MIG/CXCL9 and IP-10/CXCL10 at the tumor site compared to diluent treated control tumor bearing mice (p &#x0003c; 0.001). Assessment of cytokine production at the tumor site of SLC/CCL21 treated mice receiving anti-IFN&#x003b3;, anti MIG/CXCL9 and anti IP-10/CXCL10 showed an interdependence of IFN&#x003b3;, MIG/CXCL9 and IP-10/CXCL10: neutralization of any one of these cytokines <italic>in vivo </italic>caused a concomitant decrease in all three cytokines (*p &#x0003c; 0.01 compared to the control antibody treated group). Results are expressed as pg/mg of total protein. Total protein was determined by the Bradford assay. n= 8 mice per group</p></caption><graphic xlink:href="1476-4598-2-22-2"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Neutralization of IP-10, MIG and IFN&#x003b3; reduces the frequency of CD3<sup>+</sup>CXCR3<sup>+ </sup>T lymphocytes and CD11C<sup>+ </sup>DEC205<sup>+ </sup>DC at the tumor site of SLC/CCL21-treated mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold>+ Anti IP-10</bold></td><td align="center" colspan="2"><bold>+ Anti MIG</bold></td><td align="center" colspan="2"><bold>+ Anti IFN&#x003b3;</bold></td><td align="center" colspan="2"><bold>+ anti Control Ab</bold></td><td align="center" colspan="2"><bold>Diluent Control</bold></td></tr><tr><td></td><td align="center">%</td><td align="center">MCF</td><td align="center">%</td><td align="center">MCF</td><td align="center">%</td><td align="center">MCF</td><td align="center">%</td><td align="center">MCF</td><td align="center">%</td><td align="center">MCF</td></tr></thead><tbody><tr><td align="left"><bold>CD4</bold></td><td align="center">13</td><td align="center">44</td><td align="center">14</td><td align="center">47</td><td align="center">13</td><td align="center">40</td><td align="center">*13</td><td align="center">42</td><td align="center">*6</td><td align="center">48</td></tr><tr><td align="left"><bold>CD8</bold></td><td align="center">35</td><td align="center">57</td><td align="center">34</td><td align="center">55</td><td align="center">32</td><td align="center">50</td><td align="center">*33</td><td align="center">52</td><td align="center">*26</td><td align="center">52</td></tr><tr><td align="left"><bold>CD3CXCR3</bold></td><td align="center">**28</td><td align="center">58</td><td align="center">**27</td><td align="center">57</td><td align="center">**23</td><td align="center">55</td><td align="center">* 34</td><td align="center">59</td><td align="center">*12</td><td align="center">58</td></tr><tr><td align="left"><bold>CD11C<sup>+</sup>DEC 205<sup>+</sup></bold></td><td align="center">**10</td><td align="center">111</td><td align="center">**9</td><td align="center">110</td><td align="center">**11</td><td align="center">101</td><td align="center">*14</td><td align="center">105</td><td align="center">*4</td><td align="center">100</td></tr></tbody></table><table-wrap-foot><p>Single cell suspensions of non-necrotic tumor nodules from SLC/CCL21 treated mice receiving neutralizing antibodies to P-10/CXCL10, MIG/CXCL9, IFN&#x003b3;, control Ab and diluent treated tumor bearing mice were prepared. Cell surface staining for T cell markers CD4, CD8, CD3, and the chemokine receptor CXCR3 as well as DC markers CD11C and DEC205 were evaluated by flow cytometry. Cells were identified as lymphocytes or DC by gating on the forward and side scatter profiles; 10,000 gated events were collected and analyzed using Cell Quest software. Within the gated T lymphocyte population, intratumoral injection of SLC/CCL21 led to an increase in the frequency of CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CXCR3<sup>+ </sup>events compared to the diluent control (*p &#x0003c; 0.001). Within the gated DC population, intratumoral injection of SLC/CCL21 led to an increase in the frequency of CD11C<sup>+</sup>DEC205<sup>+ </sup>events compared to the diluent control (*p &#x0003c; 0.001). Compared to SLC/CCL21-treated mice receiving control antibody, mice receiving neutralizing antibodies to IP-10/CXCL10, MIG/CXCL9, and IFN&#x003b3; showed decrease in the gated CD3<sup>+</sup>CXCR3<sup>+ </sup>T cell as well as CD11C<sup>+</sup>DEC205 <sup>+ </sup>DC events (**p &#x0003c; 0.01) (n = 8 mice per group). MCF is mean channel fluorescence intensity. CD3<sup>+</sup>CXCR3<sup>+ </sup>MCF is for CXCR3. CD11C<sup>+</sup>DEC205<sup>+</sup>, MCF is for DEC205.</p></table-wrap-foot></table-wrap></sec><sec><title>Conclusions</title><p>Our results suggest that the anti-tumor properties of SLC/CCL21 may be due to its chemotactic capacity in co-localization of DC and T cells as well as in part to the induction of key cytokines such as IFN&#x003b3;, IP-10/CXCL10 and MIG/CXCL9.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Reagents</title><p>Abs to murine IFN&#x003b3;, recombinant IFN&#x003b3; were obtained from PharMingen (San Diego, CA). Abs to murine MIG/CXCL9, IP-10/CXCL10 and recombinant cytokine standards was purchased from R&#x00026;D (Minneapolis, MN). Recombinant SLC/CCL21 was obtained from PeproTech. (Rocky Hill, NJ). Polyclonal goat anti-murine MIG/CXCL9 and anti-murine IP-10/CXCL10 specific anti-serum were produced and characterized as previously described [<xref ref-type="bibr" rid="B31">31</xref>]. Anti-mouse IFN&#x003b3; monoclonal (R4-462, American Type Culture Collection, Rockville, Maryland, MD) neutralizing antibody was purified by affinity chromatography from SCID mice ascites, which was generated 3&#x02013;4 weeks after intraperitoneal injection of 10<sup>6 </sup>R4-462 hybridoma cells per mouse [<xref ref-type="bibr" rid="B32">32</xref>]. For flow cytometry, labeled antibodies (FITC, PE, PerCP) against the T cell surface markers to CD3, CD4, CD8 and against the DC markers, CD11c and DEC 205 and the appropriate controls were purchased from PharMingen. FITC labeled anti-rabbit IgG was purchased from PharMingen. Rabbit anti-mouse CXCR3 antibody was purchased from Zymed Laboratories Inc. (So. San Francisco, CA). Murine serum albumin (Sigma, St. Louis, MO) was utilized as control injections for SLC/CCL21.</p></sec><sec><title>Cell culture and tumorigenesis model</title><p>A weakly immunogenic lung cancer, Lewis lung carcinoma (3LL, H-2<sup>b</sup>) obtained from ATCC (CRL-1642, LLC) was utilized for assessment of cytokines important for SLC/CCL21 &#x02013; mediated anti-tumor responses <italic>in vivo</italic>. The cells were routinely cultured as monolayers in 25 cm<sup>3 </sup>tissue culture flasks containing RPMI 1640 medium (Irvine Scientific, Santa Anna, CA) supplemented with 10% fetal bovine serum (FBS) (Gemini Bioproducts, Calabasas, CA), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2 mM glutamine (JRH Biosciences, Lenexa, KS) and maintained at 37&#x000b0;C in a humidified atmosphere containing 5% CO<sub>2 </sub>in air. The cell lines were mycoplasma free and cells were utilized up to the tenth passage before thawing frozen stock cells from liquid N<sub>2</sub>.</p><p>For tumorigenesis experiments, 10<sup>5 </sup>3LL tumor cells were inoculated by s.c. injection in the right supra scapular area of C57Bl/6 mice and tumor volumes were monitored three times each week. Five day established tumors were treated with intratumoral injection of 0.5 &#x003bc;g of recombinant murine SLC/CCL21 (Pepro Tech, Rocky Hill, NJ) or murine serum albumin (utilized as an irrelevant protein for control injections) were administered three times per week for two weeks as previously described [<xref ref-type="bibr" rid="B9">9</xref>]. 24 h prior to SLC/CCL21 treatment, and then three times a week, mice were injected i.p. with 1 ml/dose of anti-IP-10/CXCL10, or anti-MIG/CXCL9, or 100 &#x003bc;g/dose of purified monoclonal anti-IFN&#x003b3; or appropriate control antibodies (goat IgG and rat IgG) at equivalent doses for the duration of the experiment. In response to these antibodies, there was a significant reduction of the respective cytokines <italic>in vivo </italic>(Figure <xref ref-type="fig" rid="F2">2</xref>). Tumor volume was calculated as previously described [<xref ref-type="bibr" rid="B9">9</xref>].</p></sec><sec><title>Cytokine ELISA</title><p>MIG/CXCL9, IP-10/CXCL10 and IFN&#x003b3; were quantified using a modification of a double ligand method as previously described [<xref ref-type="bibr" rid="B33">33</xref>].</p></sec><sec><title>Flow Cytometry</title><p>Flow cytometric analyses for T cell and DC markers were performed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA) in the University of California, Los Angeles, Jonsson Cancer Center Flow Cytometry Core Facility. Cells were identified as lymphocytes or DC by gating based on forward and side scatter profiles. CD11c<sup>+ve </sup>DCs were defined as the bright populations within tumor nodules. 10,000-gated events were collected and analyzed using Cell Quest software (Becton Dickinson). For staining, two or three fluorochromes (PE, FITC, PerCP) (PharMingen) were used to gate on the CD3, CD4 and CD8 T lymphocyte population or CD11c <sup>+ve </sup>DC in single cell suspensions from tumor nodule. For CXCR3 expression, T cells were doubly stained for CD3 and CXCR3 cell surface markers.</p></sec><sec><title>Statistical Analysis</title><p>Groups of 8 mice were used. Statistical analyses of the data in figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref> and in table <xref ref-type="table" rid="T1">1</xref> were performed using the paired Student t test.</p></sec></sec><sec><title>Author's contributions</title><p>Author 1 SS and Author 2 SCY coordinated and carried out all the experiments. Authors SH, LXZ, MH, RKB and MDB contributed to the discussion of the article. Author JFL together with SS performed the statistical analyses. Authors RMS and SMD together with SS conceived of the study, participated in its design and drafted the manuscript.</p><p>All authors read and approved the final manuscript</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Kimberly Atianzar for excellent technical assistance in conducting the ELISA measurements. National Institutes of Health Grant R01 CA78654, CA85686, P50 CA90388, Medical Research Funds from the Department of Veterans Affairs, The Research Enhancement Award Program in Cancer Gene Medicine and the Tobacco-Related Disease Research Program of the University of California supported this work.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cyster J</surname><given-names>G</given-names></name></person-group><article-title>Chemokines and the Homing of Dendritic Cells to the T Cell Areas of Lymphoid Organs</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>447</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">9927506</pub-id><pub-id pub-id-type="doi">10.1084/jem.189.3.447</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Itakura</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name></person-group><article-title>Chemotactic Response Toward Chemokines and Its Regulation by Transforming Growth Factor-beta1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>3225</fpage><lpage>3232</lpage><pub-id pub-id-type="pmid">10233873</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>VW</given-names></name><name><surname>Kothakota</surname><given-names>S</given-names></name><name><surname>Rohan</surname><given-names>MC</given-names></name><name><surname>Panganiban-Lustan</surname><given-names>L</given-names></name><name><surname>Gardner</surname><given-names>JP</given-names></name><name><surname>Wachowicz</surname><given-names>MS</given-names></name><name><surname>Winter</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group><article-title>Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>3610</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10339465</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hedrick</surname><given-names>JA</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name></person-group><article-title>Identification and characterization of a novel beta chemokine containing six conserved cysteines</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>1589</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">9257816</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hromas</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Klemsz</surname><given-names>M</given-names></name><name><surname>Krathwohl</surname><given-names>M</given-names></name><name><surname>Fife</surname><given-names>K</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Schnizlein-Bick</surname><given-names>C</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name></person-group><article-title>Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>2554</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9300671</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagira</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Tabira</surname><given-names>Y</given-names></name><name><surname>Akagi</surname><given-names>J</given-names></name><name><surname>Nomiyama</surname><given-names>H</given-names></name><name><surname>Yoshie</surname><given-names>O</given-names></name></person-group><article-title>A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells</article-title><source>Eur J Immunol</source><year>1998</year><volume>28</volume><fpage>1516</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9603456</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199805)28:05&#x0003c;1516::AID-IMMU1516&#x0003e;3.0.CO;2-J</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Quackenbush</surname><given-names>EJ</given-names></name><name><surname>Berman</surname><given-names>MA</given-names></name><name><surname>Collins-Racie</surname><given-names>LA</given-names></name><name><surname>Mi</surname><given-names>S</given-names></name><name><surname>Reilly</surname><given-names>C</given-names></name><name><surname>Lo</surname><given-names>D</given-names></name><name><surname>Jacobs</surname><given-names>KA</given-names></name><name><surname>Dorf</surname><given-names>ME</given-names></name></person-group><article-title>Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>5671</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9548511</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willimann</surname><given-names>K</given-names></name><name><surname>Legler</surname><given-names>DF</given-names></name><name><surname>Loetscher</surname><given-names>M</given-names></name><name><surname>Roos</surname><given-names>RS</given-names></name><name><surname>Delgado</surname><given-names>MB</given-names></name><name><surname>Clark-Lewis</surname><given-names>I</given-names></name><name><surname>Baggiolini</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name></person-group><article-title>The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7</article-title><source>Eur J Immunol</source><year>1998</year><volume>28</volume><fpage>2025</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9645384</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199806)28:06&#x0003c;2025::AID-IMMU2025&#x0003e;3.0.CO;2-C</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Stolina</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name><name><surname>Burdick</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>LX</given-names></name><name><surname>Batra</surname><given-names>RK</given-names></name><name><surname>Dubinett</surname><given-names>SM</given-names></name></person-group><article-title>Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>4558</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">10779757</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Stolina</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Strieter</surname><given-names>R</given-names></name><name><surname>Dubinett</surname><given-names>S</given-names></name></person-group><article-title>Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma</article-title><source>Cancer Research</source><year>2001</year><volume>61</volume><fpage>6406</fpage><lpage>6412</lpage><pub-id pub-id-type="pmid">11522634</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taub</surname><given-names>DD</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Conlon</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Ortaldo</surname><given-names>JR</given-names></name><name><surname>Harada</surname><given-names>A</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Kelvin</surname><given-names>DJ</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name></person-group><article-title>Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells</article-title><source>J Exp Med</source><year>1993</year><volume>177</volume><fpage>1809</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">8496693</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>F</given-names></name><name><surname>Rabin</surname><given-names>RL</given-names></name><name><surname>Yannelli</surname><given-names>JR</given-names></name><name><surname>Koniaris</surname><given-names>LG</given-names></name><name><surname>Vanguri</surname><given-names>P</given-names></name><name><surname>Farber</surname><given-names>JM</given-names></name></person-group><article-title>Human Mig chemokine: biochemical and functional characterization</article-title><source>J Exp Med</source><year>1995</year><volume>182</volume><fpage>1301</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">7595201</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loetscher</surname><given-names>M</given-names></name><name><surname>Gerber</surname><given-names>B</given-names></name><name><surname>Loetscher</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Piali</surname><given-names>L</given-names></name><name><surname>Clark-Lewis</surname><given-names>I</given-names></name><name><surname>Baggiolini</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name></person-group><article-title>Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes [see comments]</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>963</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9064356</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strieter</surname><given-names>RM</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Arenberg</surname><given-names>DA</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Polverini</surname><given-names>PJ</given-names></name></person-group><article-title>Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis</article-title><source>Biochem Biophys Res Commun</source><year>1995</year><volume>210</volume><fpage>51</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7537965</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1995.1626</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Addison</surname><given-names>C</given-names></name><name><surname>Arenberg</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Burdick</surname><given-names>M</given-names></name><name><surname>Mulligan</surname><given-names>M</given-names></name><name><surname>Iannettoni</surname><given-names>M</given-names></name><name><surname>Strieter</surname><given-names>R</given-names></name></person-group><article-title>The CXC chemokine, monokine induced by interferon gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis</article-title><source>Hum Gene Ther</source><year>2000</year><volume>11</volume><fpage>247</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10680839</pub-id><pub-id pub-id-type="doi">10.1089/10430340050015996</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tannenbaum</surname><given-names>CS</given-names></name><name><surname>Tubbs</surname><given-names>R</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Finke</surname><given-names>JH</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Hamilton</surname><given-names>TA</given-names></name></person-group><article-title>The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>927</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9670971</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arenberg</surname><given-names>DA</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Polverini</surname><given-names>PJ</given-names></name><name><surname>Morris</surname><given-names>SB</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Glass</surname><given-names>MC</given-names></name><name><surname>Taub</surname><given-names>DT</given-names></name><name><surname>Iannettoni</surname><given-names>MD</given-names></name><name><surname>Whyte</surname><given-names>RI</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name></person-group><article-title>Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>981</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9064358</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanegane</surname><given-names>C</given-names></name><name><surname>Sgadari</surname><given-names>C</given-names></name><name><surname>Kanegane</surname><given-names>H</given-names></name><name><surname>Feldstein</surname><given-names>tJ</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Farber</surname><given-names>JM</given-names></name><name><surname>Liao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Tosato</surname><given-names>G</given-names></name></person-group><article-title>Contribution of the CXC chemokines IP-10 and Mig to theantitumor effects of IL-12</article-title><source>J Leukocyte Biol</source><year>1998</year><volume>64</volume><fpage>384</fpage><pub-id pub-id-type="pmid">9738666</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pertl</surname><given-names>U</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Varki</surname><given-names>NM</given-names></name><name><surname>Homann</surname><given-names>D</given-names></name><name><surname>Gaedicke</surname><given-names>G</given-names></name><name><surname>Reisfeld</surname><given-names>RA</given-names></name><name><surname>Lode</surname><given-names>HN</given-names></name></person-group><article-title>IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>6944</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11359856</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>AYC</given-names></name><name><surname>Golumbek</surname><given-names>P</given-names></name><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Jaffee</surname><given-names>E</given-names></name><name><surname>Pardoll</surname><given-names>D</given-names></name><name><surname>Levitsky</surname><given-names>H</given-names></name></person-group><article-title>Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens</article-title><source>Science</source><year>1994</year><volume>264</volume><fpage>961</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">7513904</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Girgis</surname><given-names>KR</given-names></name><name><surname>Cunningham</surname><given-names>HT</given-names></name><name><surname>Meny</surname><given-names>GM</given-names></name><name><surname>Nadaf</surname><given-names>S</given-names></name><name><surname>Kavanaugh</surname><given-names>D</given-names></name><name><surname>Carbone</surname><given-names>DP</given-names></name></person-group><article-title>Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>1096</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">8837607</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Z</given-names></name><name><surname>Noffz</surname><given-names>G</given-names></name><name><surname>Mohaupt</surname><given-names>M</given-names></name><name><surname>Blankenstein</surname><given-names>T</given-names></name></person-group><article-title>Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>770</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">9218594</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Corak</surname><given-names>J</given-names></name><name><surname>Ciernik</surname><given-names>IF</given-names></name><name><surname>Kavanaugh</surname><given-names>D</given-names></name><name><surname>Carbone</surname><given-names>DP</given-names></name></person-group><article-title>Decreased antigen presentation by dendritic cells in patients with breast cancer</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>483</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9815709</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname><given-names>D</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><name><surname>Ran</surname><given-names>S</given-names></name><name><surname>Kravtsov</surname><given-names>V</given-names></name><name><surname>Nadaf</surname><given-names>S</given-names></name><name><surname>Carbone</surname><given-names>DP</given-names></name></person-group><article-title>Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>4150</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">9834220</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arenberg</surname><given-names>DA</given-names></name><name><surname>Zlotnick</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>SRB</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name></person-group><article-title>The murine CC chemokine, 6Ckine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model</article-title><source>Cancer Immunology Immunotherapy</source><year>2000</year><volume>49</volume><fpage>587</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1007/s002620000147</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>AP</given-names></name><name><surname>Yahia</surname><given-names>SA</given-names></name><name><surname>Chemin</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name><name><surname>Caux</surname><given-names>C</given-names></name></person-group><article-title>Antitumor effects of the Mouse Chemokine 6Ckine/SLC through angiostatic and Immunological mechanisms</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>1992</fpage><lpage>2000</lpage><pub-id pub-id-type="pmid">10925282</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>CJ</given-names></name><name><surname>Hartigan-O'Connor</surname><given-names>D</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Chamberlain</surname><given-names>JS</given-names></name><name><surname>Giedlin</surname><given-names>M</given-names></name><name><surname>Aukerman</surname><given-names>L</given-names></name><name><surname>Mule</surname><given-names>JJ</given-names></name></person-group><article-title>T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>2062</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11280767</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Gilbert</surname><given-names>DJ</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Hedrick</surname><given-names>J</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name></person-group><article-title>The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>8205</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9653165</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.14.8205</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arenberg</surname><given-names>D</given-names></name><name><surname>Zlotnick</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>S</given-names></name><name><surname>Burdick</surname><given-names>M</given-names></name><name><surname>Strieter</surname><given-names>R</given-names></name></person-group><article-title>Inhibition of lung cancer growth by the novel chemokine 6C-kine</article-title><source>Am J Resp Crit Care Med</source><year>1999</year><volume>159</volume><fpage>A746</fpage></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farber</surname><given-names>JM</given-names></name></person-group><article-title>Mig and IP-10: CXC chemokines that target lymphocytes</article-title><source>J Leukoc Biol</source><year>1997</year><volume>61</volume><fpage>246</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">9060447</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Keane</surname><given-names>MP</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Lynch</surname><given-names>JP</given-names><suffix>3rd</suffix></name><name><surname>Xue</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Ross</surname><given-names>DJ</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name></person-group><article-title>Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>1037</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">12097412</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spitalny</surname><given-names>GL</given-names></name><name><surname>Havell</surname><given-names>EA</given-names></name></person-group><article-title>Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities</article-title><source>J Exp Med</source><year>1984</year><volume>159</volume><fpage>1560</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6425450</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Standiford</surname><given-names>TJ</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Basha</surname><given-names>MA</given-names></name><name><surname>Chensue</surname><given-names>SW</given-names></name><name><surname>III</surname><given-names>JPL</given-names></name><name><surname>Toews</surname><given-names>GB</given-names></name><name><surname>Westwick</surname><given-names>J</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name></person-group><article-title>Interleukin-8 gene expression by a pulmonary epithelial cell line: A model for cytokine networks in the lung</article-title><source>J Clin Invest</source><year>1953</year><volume>86</volume><fpage>1945</fpage><lpage>1990</lpage><pub-id pub-id-type="pmid">2254454</pub-id></citation></ref></ref-list></back></article> 